Lonza
Provides cells, media, and reagents integrated into 3D bioprinting workflows for advanced cell culture and tissue constructs, enabling pharmaceutical and biotech research.
- CEO / Founder
- Wolfgang Wienand
- Team Size
- 10000+
- Stage
- Active
- Latest Round
- IPO
- Key Investors
- BlackRock, Inc.; UBS Fund Management (Switzerland) AG
Technology & Products
Key Products
Primary cells; Cell culture media; Bioinks; Reagents for 3D cell culture
Technological Advantage
Proprietary cell lines and media formulations optimized for 3D bioprinting applications, protected by trade secrets and manufacturing know-how; partnerships with bioprinting hardware companies create ecosystem lock-in.
Differentiation
Value Proposition
Accelerates drug discovery and tissue engineering by supplying validated biological materials that reduce development timelines by 30-50% and improve reproducibility in 3D bioprinted models.
How They Differentiate
Unlike general lab suppliers, Lonza offers specialized materials validated specifically for 3D bioprinting workflows, with 40% higher cell viability in printed constructs compared to standard alternatives.
Market & Competition
Target Customers
Pharmaceutical companies, biotech firms, academic research institutions
Industry Verticals
Pharmaceutical; Biotechnology; Medical Research
Competitors
Thermo Fisher Scientific; Merck KGaA; STEMCELL Technologies
Growth & Milestones
Growth Metrics
2023 sales CHF 6.7 billion (7.9% AER growth); 2025 sales CHF 6.5 billion; approximately 14,500 employees globally.
Major Milestones
Founded 1897; Listed on SIX Swiss Exchange; 2025 Vacaville acquisition ($1.2B); Partnerships with CELLINK and Allevi for 3D bioprinting
Notable Customers
Vertex